MOR - MorphoSys AG

NYSEArca - Nasdaq Real Time Price. Currency in USD
29.23
+0.57 (+1.99%)
At close: 4:00PM EDT

28.49 -0.74 (-2.53%)
Pre-Market: 4:09AM EDT

Stock chart is not supported by your current browser
Previous Close28.66
Open28.26
Bid28.98 x 1000
Ask29.29 x 900
Day's Range28.12 - 29.23
52 Week Range24.90 - 29.23
Volume80,252
Avg. Volume113,029
Market Cap3.606B
Beta1.00
PE Ratio (TTM)N/A
EPS (TTM)-0.74
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • ACCESSWIRE5 days ago

    MorphoSys Presents Clinical Data with Blood Cancer Candidate MOR208 in Chronic Lymphocytic Leukemia at EHA 2018 Conference

    PLANEGG and MUNICH, GERMANY / ACCESSWIRE / June 15, 2018 / MorphoSys AG (NASDAQ: MOR), (FSE: MOR), (XETRA: MOR) today announced the presentation of clinical data from the exploratory phase 2 COSMOS trial. ...

  • ACCESSWIRE5 days ago

    MorphoSys Presents Updated Clinical Data for Anti-CD38 Antibody MOR202 in Multiple Myeloma at EHA 2018

    PLANEGG and MUNICH, GERMANY / ACCESSWIRE / June 15, 2018 / MorphoSys AG (MOR), (MOR), (MOR.DE) today presented updated data from the ongoing phase 1/2a study of the anti-CD38 antibody MOR202 in relapsed/refractory multiple myeloma at the European Hematology Association (EHA) Annual Meeting 2018 in Stockholm. The dose escalation trial comprises three arms: MOR202, MOR202 in combination with the immunomodulatory drug (IMiD) lenalidomide (LEN), and MOR202 in combination with the IMiD pomalidomide (POM), in each case with low-dose dexamethasone (DEX). "We are optimistic about the responses seen in patients with multiple myeloma treated with MOR202 plus LEN/DEX and POM/DEX based on matured data as well as about the low proportion of patients experiencing infusion-related reactions," commented Dr. Malte Peters, Chief Development Officer of MorphoSys AG.

  • ACCESSWIRE8 days ago

    New Phase 3 Clinical Trials by MorphoSys's Partner with Gantenerumab in Early Alzheimer's Disease now Underway

    PLANEGG and MUNICH, GERMANY / ACCESSWIRE / June 12, 2018 / MorphoSys AG (NASDAQ: MOR, OTC PINK: MPSYY, FSE: MOR, XETRA: MOR, Prime Standard Segment, TecDAX) announced today that the first patient has been enrolled in a new phase 3 trial of gantenerumab in patients with early Alzheimer's disease. Gantenerumab is a monoclonal antibody directed against amyloid-beta generated by MorphoSys using its proprietary HuCAL antibody technology. Roche is fully responsible for the clinical development of gantenerumab.

  • ACCESSWIRE16 days ago

    MorphoSys to Present at Upcoming Investor Conferences

    PLANEGG and MUNICH, GERMANY / ACCESSWIRE / June 4, 2018 / MorphoSys AG (NASDAQ: MOR, OTC PINK: MPSYY, FSE: MOR, XETRA, MOR, Prime Standard Segment, TecDAX) will present at the following conferences: dbAccess ...

  • Who Are The Top Investors In MorphoSys AG (ETR:MOR)?
    Simply Wall St.20 days ago

    Who Are The Top Investors In MorphoSys AG (ETR:MOR)?

    I am going to take a deep dive into MorphoSys AG’s (XTRA:MOR) most recent ownership structure, not a frequent subject of discussion among individual investors. The impact of a company’sRead More...

  • ACCESSWIRElast month

    MorphoSys to Present at Upcoming Investor Conferences

    PLANEGG and MUNICH, GERMANY / ACCESSWIRE / May 18, 2018 / MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC PINK: MPSYY; NASDAQ: MOR) will present at the following conferences: UBS Global Healthcare ...

  • ACCESSWIRElast month

    Annual General Meeting of MorphoSys AG Elects New Supervisory Board Members

    At the AGM 2018 of MorphoSys AG, 60.69% of the current share capital was represented. After the AGM, the Supervisory Board in its inaugural meeting elected Dr. Marc Cluzel as its new Chairman and Dr. Frank Morich as Deputy Chairman.

  • ACCESSWIRElast month

    MorphoSys Announces Presentation of Clinical Data on Proprietary Blood Cancer Programs at Upcoming EHA 2018 Conference

    NASDAQ: MOR) today announced the publication of two abstracts on its proprietary hemato-oncological drug candidates MOR208 and MOR202 submitted to the 23rd European Hematology Association (EHA) Annual Meeting, to be held in Stockholm/Sweden from June 14-17, 2018. In a poster presentation, first clinical data from the exploratory phase 2 COSMOS trial with the Fc-engineered CD19 antibody MOR208 in combination with idelalisib in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), after discontinuation of an ibrutinib therapy, will be presented. In an oral presentation, updated maturing data from a phase 1/2a study with the CD38 antibody MOR202 alone and in combination with pomalidomide or lenalidomide in relapsed/refractory multiple myeloma will be presented.

  • ACCESSWIRE2 months ago

    MorphoSys AG Reports First Quarter 2018 Results

    Conference call and webcast (in English) to be held on May 3, 2018, at 2:00pm CEST (1:00pm BST/8:00am EDT) - Successful capital increase and U.S. Nasdaq listing closed in April 2018 with total gross proceeds ...

  • ACCESSWIRE2 months ago

    MorphoSys and Galapagos Announce Initiation of the IGUANA Phase 2 Clinical Trial with MOR106 in Atopic Dermatitis Patients

    OTC: MPSYY) and Galapagos NV (GLPG) announced today that the first patient has been enrolled in IGUANA, a phase 2 study with MOR106, an investigational antibody directed against IL-17C, in atopic dermatitis patients. At least 180 patients with moderate-to-severe atopic dermatitis (AD) are planned be treated over a 12-week period with one of three different doses of MOR106 (1, 3 or 10 mg/kg) or placebo using two different dosing regimens in this phase 2 trial in multiple centers across Europe. ''Moderate-to-severe AD is a chronic, debilitating disease affecting millions of patients worldwide,'' said Dr. Malte Peters, Chief Development Officer of MorphoSys AG.

  • ACCESSWIRE2 months ago

    MorphoSys Announces Approval of Tremfya(R) (Guselkumab) in South Korea

    NASDAQ: MOR) announced today that an affiliate of its licensee, Janssen Korea Ltd. (Janssen), reported that South Korea's Ministry of Food and Drug Safety has approved Tremfya(R) (guselkumab) for the treatment of moderate to severe adult plaque psoriasis requiring phototherapy or systemic therapies. Tremfya(R) is a fully human anti-IL-23 monoclonal antibody developed by Janssen Research & Development, LLC and was generated utilizing MorphoSys's proprietary HuCAL antibody library technology. MorphoSys is eligible to receive royalties on net sales of Tremfya(R).

  • ACCESSWIRE2 months ago

    MorphoSys AG: Updated Corporate Calendar 2018

    PLANEGG/MUNICH, GERMANY PLANEGG and MUNICH, GERMANY / ACCESSWIRE / April 25, 2018 / Please note MorphoSys's updated financial reporting dates for the remainder of 2018. After the successful listing at ...

  • ACCESSWIRE2 months ago

    MorphoSys Announces Closing of Nasdaq IPO through an ADS Offering and Exercise of the Underwriters' Option to Purchase Additional ADSs, Leading to Total Gross Proceeds of USD 239 million

    PLANEGG and MUNICH, GERMANY / ACCESSWIRE / April 23, 2018 / MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC PINK: MPSYY; NASDAQ: MOR) announced today the closing of its initial public offering ...

  • GlobeNewswire2 months ago

    Nasdaq Welcomes MorphoSys AG (Nasdaq: MOR) to The Nasdaq Stock Market

    NEW YORK, April 19, 2018-- MorphoSys AG, a late-stage biopharmaceutical company devoted to the development of innovative and differentiated therapies for patients suffering from serious diseases, visited ...